A Randomized, Double-Blind, Multicentre, Phase II Controlled Trial Assessing Zactima (Vandetanib) Against Placebo in Prolonging the Off-Treatment Interval in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy.

Trial Profile

A Randomized, Double-Blind, Multicentre, Phase II Controlled Trial Assessing Zactima (Vandetanib) Against Placebo in Prolonging the Off-Treatment Interval in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2016

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ZENITH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Dec 2010 Planned End Date changed from 1 Apr 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
    • 03 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top